HHS bypasses FDA to expand access to six unproven peptide injections

The U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., has issued an interim enforcement policy directing the FDA not to take regulatory action against compounding pharmacies that prepare six unapproved peptide injections: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. The move effectively bypasses the FDA's formal drug review process — and was made with little input from FDA scientists, who largely opposed it, warning it could undermine the agency's core mission of keeping unsafe products off the market.

The six peptides are proposed for a range of conditions including ulcerative colitis, insomnia, wound healing, obesity, osteoporosis, and migraines. None have passed FDA review for safety or efficacy, and in 2023, the FDA had added BPC-157 and TB-500 to a list of substances pharmacies shouldn't compound, citing risks of tumor growth, kidney damage, and allergic reactions. Telehealth company Hims & Hers has already signaled plans to sell these peptides once rules change, in a market analysts value at over $2 billion.

Key Takeaways:

• Prescribing physicians bear direct responsibility for informed consent and adverse event reporting
• FDA-approved alternatives already exist for many of the conditions these peptides target (e.g., insomnia, migraines)
• Pharmacies must source ingredients from FDA-registered facilities and track side effects — but experts note the FDA lacks legal authority to enforce these requirements
• Long-term safety data, including cancer risk, remains largely absent for all six compounds

Why it matters: This policy sets a significant precedent by allowing HHS to sidestep the FDA's standard drug review process. Clinicians should be prepared for patients who may mistakenly view this as FDA approval — and should document informed consent carefully if they choose to prescribe these compounds.